
Powered by the Sharekhan 3R Research Philosophy



| ESG I | NEW | | | | |
|---------------------|-------|-----|------|--------|--|
| ESG RI | 25.33 | | | | |
| Medium Risk | | | | | |
| NEGL | LOW | MED | HIGH | SEVERE | |
| 0-10 | 40+ | | | | |
| Source: Morningstar | | | | | |


Company details

| Market cap: | Rs. 26,091 cr |
|-------------------------------|---------------|
| 52-week high/low: | Rs. 886 / 628 |
| NSE volume: (No of shares) | 8.9 lakh |
| BSE code: | 500271 |
| NSE code: | MFSL |
| Free float: (No of shares) | 21.7 cr |

Shareholding (%)

| Promoters | 11.5 |
|-----------|------|
| FII | 44.8 |
| DII | 36.0 |
| Others | 7.7 |

Price chart



Price performance

| (%) | 1m | 3m | 6m | 12m |
|-------------------------------|-----|-----|------|-------|
| Absolute | 1.9 | 6.0 | -4.9 | -13.0 |
| Relative to Sensex | 2.9 | 6.3 | -8.9 | -16.2 |
| Sharekhan Research, Bloomberg | | | | |

Max Financial Services Ltd

New product launched drives higher margins

| Insurance | | | | S | hare | khan code: MFSL | |
|----------------|----------|-------------------|-------------------|--------------------|----------|------------------------------|--------------|
| Reco/View: Buy | | \leftrightarrow | CN | MP: Rs. 7 ! | 56 | Price Target: Rs. 950 | \downarrow |
| | 1 | Upgrade | \leftrightarrow | Maintain | <u> </u> | Downgrade | |

Summary

- Max Life reported ~50% y-o-y VNB growth despite a 5% y-o-y decline in APE. VNB margin expanded to 39.3% in Q3FY2023 vs. 31.8% in 9MFY2023 and 24.9%/25.1% in Q3FY2022/9MFY2022, respectively. This was driven by its new non-par product, which likely had higher product margins as well.
- The share of non-PAR increased to 55% of overall APE vs. 38% q-o-q. Non-PAR savings grew at 118% y-o-y/83% q-o-q, led by a 300% y-o-y increase in the annuity segment. Income from insurance policies with a premium of more than Rs 5 lakh p.a. will not be exempt from April 2023 and will impact par and non-par business flows.
- We have factored this into our estimates. Also, we believe Q4FY2023 would be bumper growth for the non-PAR savings segment. Individual APE declined by 5% y-o-y. Retail protection grew by 2% y-o-y, while group protection fell by 19% y-o-y. PAR declined by 46% y-o-y. ULIP also saw a decline of 52% y-o-y.
- We maintain Buy with a revised PT of Rs. 950. Valuations are inexpensive after the recent sharp corrections.

Max Life reported ~12% y-o-y and 8% q-o-q growth in gross written premium. Annualised new business premium declined by 5% y-o-y reported at Rs. 1,510 crore. Value of new business (VNB) grew by 50% y-o-y reported at Rs. 593 crore. VNB margin expanded to 39.3% in Q3FY2023 vs. 31.8% in 9MFY2023 and 24.9%/25.1% in Q3FY2022/9MFY2022, respectively, aided by better product mix with higher share of non-par savings product. The share of non-PAR savings in the APE mix increased to 55% (vs. 24% in Q3FY2022); while protection at 9.8% stood flat y-o-y and PAR stood at 12% in Q3FY2023 vs. 21% in Q3FY2022. The share of ULIP stood at 23% in Q3FY2023 vs. 45% in Q3FY22. On the distribution side, Banca APE declined by 12% y-o-y; however, it picked up sequentially and grew by 36% q-o-q. Proprietary channels continued to witness healthy growth of 13% y-o-y. Axis Bank is now set to own a 20% stake in Max Life. The consideration for the balance 7% stake purchase by the bank will be significantly higher than initially envisaged, but it will likely to be compensated in the form of higher commissions from Max Life as IRDA has removed the commission caps from FY2024E.

Key positives

- Persistency improved in most buckets except the 13th month.
- Higher share of the non-par savings segment drove improvement in VNB margin.

Key negatives

Overall APE declined by 5% y-o-y on account of Banca channel APE, which declined by 12% y-o-y; however, it picked up sequentially.

Management Commentaru

- Management expects the mix of the non-par segment to be ~40% on a sustained basis in the near to medium term with annuity at ~6%. Thus, management expects VNB margin to remain at 27-28% over the medium term.
- Non-par savings APE grew by 118% y-o-y, driven by the newly launched Smart Wealth Advantage Guarantee (SWAG) product. It received tremendous response across channels. This has supported the VNB margin and VNB growth trajectory.

Our Call

Valuation – We maintain Buy on the stock with a revised PT of Rs. 950. Growth in non-par savings continues to witness strong momentum, led by new product launch. However, going forward from April 2023, we believe business flows would get impacted in this segment due to Union Budget proposal of taxing income from insurance policies with a premium of greater than Rs. 5 lakh p.a. We have factored this into our estimates. Group protection saw a decline due to pricing pressure in GTL policies, while individual protection growth remained tepid. Going forward, Max Life would have to diversify across product segments, which could support the overall growth momentum. It has been on-boarding newer bancassurance partners and newage digital players, which would not only help diversify the mix but also provide higher sales capacity for it. Hence, we believe sectoral tailwinds may result in providing a positive trigger for improving growth metrics going forward. Max Life generated stable operating RoEV of $^{\sim}19.5\%$ in 9MFY2023 and persistency trends were stable. We believe now the key catalyst would be the reverse merger of Max Financials with Max Life Insurance along with the listing of Max Life. Valuations are inexpensive, after the recent sharp correction.

Key Risks

Muted demand and any adverse regulatory policies/guidelines may affect its profitability.

| Valuation | | | | Rs cr |
|----------------|--------|--------|--------|--------|
| Particulars | FY22 | FY23E | FY24E | FY25E |
| APE (Rs cr) | 5,590 | 5,800 | 6,050 | 6,800 |
| VNB (Rs cr) | 1,530 | 1,770 | 1,650 | 1,850 |
| VNB Margin (%) | 27.4 | 30.5 | 27.3 | 27.2 |
| EV (Rs cr) | 14,170 | 16,430 | 19,350 | 28,500 |
| ROEV (%) | 19.8 | 15.4 | 18.5 | 18.0 |
| P/EV (x) | 2.3 | 2.0 | 1.7 | 1.1 |
| P/VNB (x) | 21.3 | 18.4 | 19.8 | 17.6 |

Source: Company; Sharekhan estimates



Key result highlights

- Focus on balanced product mix: Product mix improved with an increasing share of non-PAR savings. The company aims to keep the share of non-PAR savings at ~40%. The company launched Smart Wealth Advantage Guarantee (SWAG) product. The company received tremendous response across channels. This has supported the VNB margin and VNB growth trajectory. The company also launched two new protection plans, which are witnessing healthy traction and is likely to maintain the momentum going ahead. Overall, long-term opportunity in the protection business remains strong and intact.
- Improving distribution mix: The company remains focused on increasing the agent count and make investments in the agency channel, which will drive incremental growth. On the distribution side, Banca APE declined by 12% y-o-y; however, it picked up sequentially and grew by 36% q-o-q. Proprietary channels continued to witness healthy growth of 13% y-o-y. The company is aiming for sustainable growth, led by new partnerships and pick-up in the Banca channel as open architecture settles down. The company has entered into multiple partnerships to strengthen its distribution franchise. The company has entered into partnership with Ujjivan SFB and two stockbrokers.
- Stake sale transaction: Max Financial has concluded the acquisition of a 5.17% stake in MAXLIFE from MSI. Post this, Max Financial holds an 87% stake in Max Life. The last stage of the transaction is pending now, wherein Axis Bank would acquire the balance 7% stake from Max Financial. The company has entered into a revised agreement with Axis Bank and its subsidiaries to purchase the balance stake at a fair market value using the DCF method. This is as per the guidance received from the IRDAI.

Results (Max Life Insurance)

Rs cr

| Particulars | Q3FY23 | Q3FY22 | Q2FY23 | Y-o-Y % | Q-o-Q % |
|-----------------------|--------|--------|--------|---------|---------|
| Gross Written Premium | 6,284 | 5,600 | 5,801 | 12.2 | 8.3 |
| PBT | 294 | 115 | 53 | 155.7 | 454.7 |
| New Business APE | 1,510 | 1,593 | 1,191 | (5.2) | 26.8 |
| VNB | 593 | 396 | 373 | 49.7 | 59.0 |
| VNB Margins | 39.3% | 24.9% | 31.3% | | |
| Solvency Ratio | 200% | 207% | 196% | | |
| Embedded Value | 15,547 | 13,412 | 14,704 | 15.9 | 5.7 |

Source: Company; Sharekhan Research



Outlook and Valuation

■ Sector View – Strong growth outlook

Factors such as a large protection gap and expanding per capita income are key long-term growth drivers for the insurance sector in India. India has a high protection gap and credit protection product is still at an early stage and has the potential to grow multifold as the penetration of retail loans improves in the country. Hence, we believe the insurance sector has a huge growth potential in India. In this backdrop, we believe strong players armed with the right mix of products, services, and distribution are likely to gain disproportionally from the opportunity. Industry growth even during the pandemic shows a promising future for India's life insurance sector and the pandemic has highlighted the protection gap in India.

■ Company Outlook – Moving towards a balanced product mix

Max Financial Services (MFS) is building a strong franchise, characterised by a multi-channel distribution network built upon a balanced product mix. Going forward, management has indicated a balanced mix of business with non-PAR at $^{\sim}40\%$ of APE, while protection is at 35-40% of APE. We believe cost management, rebalancing of the product mix, and further diversification of distribution channels are key levers for profitability improvement, growth, and add value to business franchise. We believe now the key catalyst would be the reverse merger of Max Financials with Max Life Insurance along with the listing of Max Life.

■ Valuation – We maintain Buy on the stock with a revised PT of Rs. 950

Growth in non-par savings continues to witness strong momentum, led by new product launch. However, going forward from April 2023, we believe business flows would get impacted in this segment due to Union Budget proposal of taxing income from insurance policies with a premium of greater than Rs. 5 lakh p.a. We have factored this into our estimates. Group protection saw a decline due to pricing pressure in GTL policies, while individual protection growth remained tepid. Going forward, Max Life would have to diversify across product segments, which could support the overall growth momentum. It has been on-boarding newer bancassurance partners and new-age digital players, which would not only help diversify the mix but also provide higher sales capacity for it. Hence, we believe sectoral tailwinds may result in providing a positive trigger for improving growth metrics going forward. Max Life generated stable operating RoEV of ~19.5% in 9MFY2023 and persistency trends were stable. We believe now the key catalyst would be the reverse merger of Max Financials with Max Life Insurance along with the listing of Max Life. Valuations are inexpensive, after the recent sharp correction.



About company

Max Financial Services Limited (MFSL) is part of India's leading business conglomerate – Max Group. Focused on life insurance, MSFL currently owns a ~87% majority stake in MLI, which is the sole operating subsidiary of MFSL. Max Life is India's largest non-bank private life insurer and the fourth largest private life insurance company. MLI offers comprehensive long-term savings, protection, and retirement solutions through its high-quality agency distribution and multi-channel distribution partners.

Investment theme

MFS holds a majority stake in MLI, which is among the leading private sector insurers. The company has gained critical mass and enjoys strong operating parameters in the industry. MLI has delivered strong performance over the years. As the insurance sector is showing signs of sustained growth potential, the company's well-diversified product mix and a strong distribution channel augur well and will help sustain healthy growth in business. Strong focus towards customer measures has helped to deliver superior performance across parameters and will continue to remain an important differentiator. Key catalyst is the reverse merger of Max Financials with MLI.

Key Risks

Muted demand and any adverse regulatory policies/guidelines may affect its profitability.

Additional Data

Key management personnel

| Mr. Prashant Tripathy | MD and CEO of Max Life Insurance | | |
|-----------------------|---------------------------------------|--|--|
| Mr. Amrit Singh | CFO of Max Financial & Life Insurance | | |

Source: Company Website

Top 10 shareholders

| Sr. No. | Holder Name | Holding (%) |
|---------|--|-------------|
| 1 | MS&AD INSURANCE GROUP HOLDINGS INC. | 21.86 |
| 2 | MAX VENTURES INVESTMENT HOLDINGS PVT. LTD. | 11.33 |
| 3 | MIRAE ASSET GLOBAL INVESTMENTS CO. LTD. | 5.97 |
| 4 | ICICI PRUDENTIAL ASSET MANAGEMENT CO. LTD. | 4.54 |
| 5 | NIPPON LIFE INDIA ASSET MANAGEMENT LTD. | 4.18 |
| 6 | HDFC ASSET MANAGEMENT CO. LTD. | 3.81 |
| 7 | KOTAK MAHINDRA ASSET MANAGEMENT CO. LTD. | 3.36 |
| 8 | WF ASIAN SMALLER COS FUND. LTD. | 2.84 |
| 9 | NEW YORK LIFE INSURANCE CO. | 2.53 |
| 10 | DSP INVESTMENT MANAGERS PVT. LTD. | 2.29 |

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

| Right Sector | |
|-----------------|--|
| Positive | Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies |
| Neutral | Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies |
| Negative | Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability. |
| Right Quality | |
| Positive | Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance. |
| Neutral | Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable |
| Negative | Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and detoriating balance sheet |
| Right Valuation | |
| Positive | Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment. |
| Neutral | Trading at par to historical valuations and having limited scope of expansion in valuation multiples. |
| Negative | Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple. |

Source: Sharekhan Research



Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61150000; email id: complianceofficer@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com.

Registered Office: Sharekhan Limited, The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA, Tel: 022 - 67502000/ Fax: 022 - 24327343. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O/CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183.

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.